Corvus Pharmaceuticals, Inc. short interest in 2022
In 2022, Corvus Pharmaceuticals, Inc.'s disclosed short interest ran from 0.64% of shares outstanding on 14 Jan 2022 to 0.38% on 30 Dec 2022, a change of -0.26 percentage points. The year's high was 0.73% on 15 Feb 2022 and its low 0.32% on 15 Dec 2022, averaging 0.48% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.93 days on 30 Nov 2022. Full history: Corvus Pharmaceuticals, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 0.64% (14 Jan 2022)
- End of year
- 0.38% (30 Dec 2022)
- Change
- -0.26 pp
- High
- 0.73% (15 Feb 2022)
- Low
- 0.32% (15 Dec 2022)
- Average
- 0.48%
- Highest days to cover
- 4.93 (30 Nov 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 0.64% | 1.00 | |
| 31 Jan 2022 | 0.36% | 1.00 | |
| 15 Feb 2022 | 0.73% | 1.17 | |
| 28 Feb 2022 | 0.43% | 1.07 | |
| 15 Mar 2022 | 0.44% | 1.17 | 10-K filed, results (8-K) |
| 31 Mar 2022 | 0.46% | 1.09 | |
| 14 Apr 2022 | 0.39% | 1.00 | |
| 29 Apr 2022 | 0.42% | 1.01 | |
| 13 May 2022 | 0.53% | 1.04 | 10-Q filed, results (8-K) |
| 31 May 2022 | 0.41% | 1.03 | |
| 15 Jun 2022 | 0.49% | 1.27 | |
| 15 Aug 2022 | 0.71% | 1.00 | 10-Q filed, results (8-K) |
| 15 Sep 2022 | 0.43% | 1.37 | |
| 30 Sep 2022 | 0.44% | 1.00 | |
| 14 Oct 2022 | 0.51% | 1.70 | |
| 31 Oct 2022 | 0.44% | 1.62 | |
| 15 Nov 2022 | 0.44% | 1.18 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 0.70% | 4.93 | |
| 15 Dec 2022 | 0.32% | 1.00 | |
| 30 Dec 2022 | 0.38% | 1.70 |
See also: Corvus Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.